Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prevalence-based economic evaluation.

J Mauskopf1

  • 1Center for Economics Research, Research Triangle Institute, Research Triangle Park, NC 27709, USA. jom@rti.org

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 6, 2006
PubMed
Summary

This study introduces two new categories for economic drug evaluations: incidence-based and prevalence-based. This framework aims to provide better economic information for healthcare decision-making regarding new treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.

BJOG : an international journal of obstetrics and gynaecology·2022
Same author

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

BJOG : an international journal of obstetrics and gynaecology·2013
Same author

Alzheimer's disease: the strength of association of costs with different measures of disease severity.

The journal of nutrition, health & aging·2010
Same author

Patient preferences and assessment of likely adherence to hepatitis C virus treatment.

Journal of viral hepatitis·2010
Same author

Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.

Transplant infectious disease : an official journal of the Transplantation Society·2007
Same author

Meeting the NICE requirements: a Markov model approach.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Decision Science

Background:

  • Economic evaluations of new drugs are underutilized in healthcare decision-making.
  • Existing methods for economic drug evaluation lack a clear categorization.
  • There is a need for improved economic information to guide treatment choices.

Purpose of the Study:

  • To propose a novel categorization for economic evaluations of new drugs.
  • To differentiate between incidence-based and prevalence-based economic evaluations.
  • To enhance the usability of economic data for healthcare decision-makers.

Main Methods:

  • Categorization of economic evaluations into incidence-based and prevalence-based.
  • Description of the focus and scope of each evaluation type.

Related Experiment Videos

  • Analysis of the information provided by each category for decision-making.

    • Main Results:

    • Incidence-based evaluations assess treatment impact from onset to cure/death, focusing on value compared to alternatives.
    • Prevalence-based evaluations assess impact within a 1-year period, focusing on budget and population health.
    • Incidence-based evaluations can focus on individuals or cohorts; prevalence-based evaluations focus on populations.

    Conclusions:

    • Both incidence-based and prevalence-based economic evaluations offer crucial insights.
    • This new categorization aims to deliver more complete and actionable economic information.
    • The proposed framework supports informed healthcare decisions regarding new drug introductions.